Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration

AUTOR(ES)

Fraga, Daiane B., Réus, Gislaine Z., Abelaira, Helena M., De Luca, Renata D., Canever, Leila, Pfaffenseller, Bianca, Colpo, Gabriela D., Kapczinski, Flávio, Quevedo, João, Zugno, Alexandra I.

FONTE

Rev. Bras. Psiquiatr.

DATA DE PUBLICAÇÃO

2013-09

RESUMO

Objective: To evaluate behavioral changes and brain-derived neurotrophic factor (BDNF) levels in rats subjected to ketamine administration (25 mg/kg) for 7 days. Method: Behavioral evaluation was undertaken at 1 and 6 hours after the last injection. Results: We observed hyperlocomotion 1 hour after the last injection and a decrease in locomotion after 6 hours. Immobility time was decreased and climbing time was increased 6 hours after the last injection. BDNF levels were decreased in the prefrontal cortex and amygdala when rats were killed 6 hours after the last injection, compared to the saline group and to rats killed 1 hour after the last injection. BDNF levels in the striatum were decreased in rats killed 6 hours after the last ketamine injection, and BDNF levels in the hippocampus were decreased in the groups that were killed 1 and 6 hours after the last injection. Conclusion: These results suggest that the effects of ketamine on behavior and BDNF levels are related to the time at which they were evaluated after administration of the drug.

Documentos Relacionados

• Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania
• Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications.
• Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus.
• Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease